Ghrelin Resistance in Obesity

Ghrelin Biology

39% lower

Fasting ghrelin levels are approximately 39% lower in insulin-resistant obese adults compared to equally obese insulin-sensitive controls.

McLaughlin et al., J Clin Endocrinol Metab, 2004

McLaughlin et al., J Clin Endocrinol Metab, 2004

View as image

Ghrelin is the only known circulating hormone that stimulates appetite. In lean individuals, ghrelin rises before meals, triggers hunger through hypothalamic circuits, and falls after eating. The system is elegant and responsive. In obesity, it breaks down. Circulating ghrelin levels drop. The brain stops responding to whatever ghrelin remains. And the hormone's non-appetite functions, including cognitive protection and mood regulation, may be collateral damage. This phenomenon, called ghrelin resistance, parallels the better-known leptin resistance that also characterizes obesity, and understanding it may explain why weight regain after dieting is so persistent. For a full overview of ghrelin's biology, structure, and receptor system, see our pillar article on ghrelin: the hunger hormone that rises before meals.

The Ghrelin Paradox: Why the Hunger Hormone Is Low in Obesity

If ghrelin drives hunger, obese individuals should have elevated ghrelin. They do not. Multiple studies have confirmed that circulating ghrelin, both total and acylated forms, is lower in obese humans and rodents compared to lean controls. Papandreou et al. (2017) measured fasting ghrelin in 13 normal-weight and 7 obese young adults, finding that ghrelin was inversely correlated with BMI (r = -0.77, p < 0.001) and with insulin resistance measured by HOMA-IR (r = -0.66, p < 0.001).^[1]

This suppression is not random. It appears driven by the hyperinsulinemia that accompanies obesity. McLaughlin et al. (2004) tested this directly by comparing 20 insulin-resistant obese adults with 20 equally obese insulin-sensitive controls (matched BMI of ~32 kg/m2). Despite identical body mass, the insulin-resistant group had ghrelin levels of 252 pg/ml compared to 412 pg/ml in the insulin-sensitive group, a 39% reduction. Multivariate analysis confirmed that both insulin resistance and hyperinsulinemia independently predicted low ghrelin concentrations.^[2] This means obesity alone does not fully explain low ghrelin. The metabolic dysfunction that accompanies obesity, specifically insulin resistance and compensatory hyperinsulinemia, is an independent suppressor.

Perreault et al. (2004) documented additional disruptions in a mouse model of diet-induced obesity. High-fat diet-fed mice showed not only reduced ghrelin secretion but also loss of the normal diurnal ghrelin cycling pattern. The preprandial rise in ghrelin, which signals meal initiation in lean animals, was absent. The fasting-induced increase in ghrelin, a starvation signal that drives food-seeking behavior, also failed to occur.^[3] The ghrelin system in obesity is not just quantitatively reduced; its temporal regulation is dismantled.

Central Ghrelin Resistance: The Brain Stops Listening

Low circulating ghrelin could theoretically be compensated by increased brain sensitivity. The opposite occurs. Briggs et al. (2010) provided the most detailed characterization of central ghrelin resistance in a landmark study using diet-induced obese (DIO) mice fed a high-fat diet for 12 weeks.^[4]

The results were comprehensive. DIO suppressed the ghrelin system at every level: decreased acylated and total plasma ghrelin, decreased ghrelin and GOAT mRNA in the stomach, and decreased GHSR expression in the hypothalamus. When the researchers injected ghrelin peripherally (intraperitoneal) or directly into the brain (intracerebroventricular), it stimulated food intake and arcuate nucleus Fos immunoreactivity in chow-fed mice but failed completely in high-fat diet-fed mice.

The critical finding was identifying where resistance occurs. DIO decreased expression of both neuropeptide Y (Npy) and agouti-related peptide (Agrp) mRNA, the two key orexigenic neuropeptides downstream of ghrelin signaling. Central ghrelin injection could not rescue expression of these genes. Ghrelin also failed to stimulate NPY or AgRP secretion from hypothalamic explants taken from DIO mice, confirming the defect was at the neuronal level. When NPY was injected directly into the brain, both chow-fed and DIO mice increased food intake equally. This proved that the downstream neural targets of NPY/AgRP are intact in obesity; the problem is specifically that NPY/AgRP neurons no longer respond to ghrelin.

Briggs et al. also showed that ghrelin resistance extends beyond appetite. Ghrelin did not stimulate growth hormone secretion in DIO mice, indicating that the resistance is not confined to feeding circuits. This has implications for ghrelin's other brain functions. Ghrelin promotes cognitive function, mood regulation, and neuroprotection. Central ghrelin resistance may therefore contribute to the cognitive decline, depression risk, and accelerated brain aging associated with obesity, a connection that remains underexplored.

The Inflammation Pathway: How High-Fat Diets Damage Ghrelin Signaling

Naznin et al. (2015) identified a specific mechanism linking diet-induced obesity to ghrelin resistance: inflammation of the vagal afferent pathway.^[5] Ghrelin's primary route from the gut to the brain runs through the vagus nerve. Ghrelin activates receptors on vagal afferent neurons in the nodose ganglion (a cluster of nerve cell bodies near the base of the skull), which relay the signal to the hypothalamic arcuate nucleus.

In mice fed a high-fat diet for 12 weeks, subcutaneous ghrelin injection failed to induce food intake, suppress oxygen consumption, activate vagal afferent nerve electrical activity, trigger ERK2 and AMPK-alpha phosphorylation in the nodose ganglion, or stimulate Fos expression in the arcuate nucleus. The entire signaling cascade was blocked, from the initial vagal response to the final hypothalamic readout.

The mechanism was inflammation. High-fat diet-fed mice showed upregulation of macrophage and microglia markers in both the nodose ganglion and hypothalamus, along with increased inflammatory cytokines. GHSR mRNA expression was reduced in both locations. The study described the process as "in situ activation of inflammation," meaning the inflammation was occurring locally within the neural tissue, not simply reflecting systemic inflammatory status. The high-fat diet was physically damaging the neural infrastructure that carries ghrelin's signal.

This inflammatory mechanism connects ghrelin resistance to the broader phenomenon of diet-induced hypothalamic inflammation, which has been documented with MRI in obese humans. The same inflammatory processes that impair leptin signaling in obesity appear to simultaneously impair ghrelin signaling, creating a dual hormonal resistance state. If leptin resistance means the brain cannot properly register satiety signals, ghrelin resistance means the brain's hunger-signaling apparatus is also dysfunctional. The result is not simply "too much hunger" or "too little satiety" but a disordered system that no longer tracks energy status accurately.

Mechanisms of Resistance: A Multi-Level Breakdown

Cui, Lopez, and Rahmouni (2017) published a comprehensive review in Nature Reviews Endocrinology cataloguing the cellular and molecular mechanisms of both leptin and ghrelin resistance in obesity.^[6] They identified four distinct mechanisms through which ghrelin resistance develops:

Reduced circulating ghrelin. Chronic positive energy balance suppresses ghrelin secretion from gastric X/A-like cells. The suppression is mediated partly by elevated insulin and partly by changes in gastric cell function. Stomach cells in obese animals no longer respond normally to secretory stimuli like norepinephrine and glucose.

Impaired blood-brain barrier transport. Ghrelin must cross the blood-brain barrier (BBB) to reach hypothalamic targets. Evidence from rodent studies suggests that obesity reduces the efficiency of ghrelin transport across the BBB, though the specific transport mechanism remains debated. Whether this involves a saturable transporter, passive diffusion through fenestrated capillaries in the median eminence, or vagal nerve relay, obesity appears to impair the process.

Reduced GHSR expression. The growth hormone secretagogue receptor is downregulated in the hypothalamus during diet-induced obesity. With fewer receptors available, even normal ghrelin concentrations produce a weaker signal. This receptor downregulation may be a consequence of chronic low-grade inflammation in the hypothalamus.

Impaired NPY/AgRP neuronal function. As Briggs et al. demonstrated, the orexigenic neurons that execute ghrelin's appetite-stimulating command become unresponsive. Their baseline expression of NPY and AgRP is reduced, and they fail to increase expression in response to ghrelin stimulation. Since these neurons are the primary downstream effectors of ghrelin's orexigenic action, their dysfunction represents the final common pathway of ghrelin resistance.

These mechanisms are not mutually exclusive. They layer on top of each other in established obesity, creating redundant barriers to ghrelin signaling. This redundancy may explain why ghrelin resistance is difficult to overcome with single-target interventions.

LEAP-2: The Endogenous Ghrelin Blocker That Rises in Obesity

Adding complexity to the ghrelin resistance picture is LEAP-2 (liver-expressed antimicrobial peptide 2), identified as an endogenous antagonist of the ghrelin receptor. LEAP-2 rises after meals and in states of positive energy balance, functioning as a natural counterweight to ghrelin. In obesity, LEAP-2 levels are elevated, creating an additional layer of ghrelin suppression beyond the mechanisms described above.

The ghrelin-LEAP-2 axis operates as a bidirectional energy sensor. In fasting and negative energy balance, ghrelin rises and LEAP-2 falls, creating a strong orexigenic signal. In obesity and positive energy balance, ghrelin falls and LEAP-2 rises, suppressing ghrelin receptor activation from both sides: less agonist and more antagonist. This dual regulation may have evolved to protect against weight cycling, but in modern obesity it contributes to a state where the ghrelin system is effectively silenced. For deeper coverage of ghrelin's role in reward processing and how it intersects with obesity, see ghrelin and reward: why hunger makes food taste better.

Reversibility: What Happens When Weight Is Lost

Ghrelin resistance is not permanent. Perreault et al. (2004) demonstrated that mice made obese on a high-fat diet and then returned to a low-fat diet regained sensitivity to ghrelin's appetite-stimulating effects as they lost weight.^[3] The diurnal cycling pattern of ghrelin secretion also recovered.

This reversibility has a clinically uncomfortable implication. When an obese individual loses weight through caloric restriction, ghrelin levels rise (the suppression by hyperinsulinemia is relieved as insulin sensitivity improves) and ghrelin sensitivity returns (the central resistance resolves as hypothalamic inflammation subsides). The result is a restored, fully functional hunger signal in a person who is trying to maintain a lower body weight. This is one mechanism through which the body defends a higher weight set point: during obesity, ghrelin resistance limits further weight gain by blunting appetite drive; after weight loss, the resolution of ghrelin resistance unleashes appetite drive that promotes weight regain.

The practical consequence is that weight loss interventions face a moving target. The hormonal environment that existed during obesity (low ghrelin, central resistance) is replaced by a new hormonal environment after weight loss (rising ghrelin, restored sensitivity) that actively opposes the maintenance of a lower weight. This is not a failure of willpower; it is the ghrelin system doing exactly what it evolved to do: drive food seeking when energy reserves drop below a defended set point.

Bariatric procedures handle this differently. Sleeve gastrectomy removes the gastric fundus where most ghrelin-producing cells reside, physically reducing ghrelin production capacity. This may partly explain why surgical weight loss is more durable than dietary weight loss: the ghrelin rebound that drives dietary weight regain is structurally prevented. The relationship between GLP-1 receptor agonists and ghrelin is also relevant here; for context on how semaglutide achieves weight loss through incretin pathways, see semaglutide for weight loss without diabetes.

Implications Beyond Appetite

Ghrelin resistance in obesity may have consequences that extend beyond weight regulation. Briggs et al. (2010) explicitly noted that ghrelin has functions in the brain beyond appetite control, including cognitive function, mood regulation, and neuroprotection against neurodegenerative diseases.^[4] If central ghrelin resistance blocks these functions alongside appetite, it could contribute to several obesity-associated conditions:

Cognitive decline. Ghrelin enhances hippocampal synaptic plasticity and memory formation. Central ghrelin resistance could impair these processes, contributing to the well-documented association between obesity and accelerated cognitive decline. The mechanism would be distinct from vascular or inflammatory contributions to obesity-related cognitive impairment, operating through a specific hormonal pathway.

Depression and anhedonia. Ghrelin modulates the mesolimbic dopamine system, increasing dopamine neuron firing and enhancing the motivational salience of rewards. Central ghrelin resistance could dampen dopamine signaling, reducing the capacity for pleasure and motivation. This connects to the elevated depression risk observed in obese populations, though the causal direction is difficult to establish because depression itself alters eating behavior and body weight.

Growth hormone deficiency. Ghrelin is a potent stimulator of growth hormone release. Central ghrelin resistance in obesity suppresses this axis, contributing to the relative growth hormone deficiency seen in obese adults. Reduced growth hormone in turn promotes further fat accumulation and muscle loss, potentially creating a positive feedback loop. For more on the dual growth hormone and appetite functions of ghrelin, see how ghrelin stimulates growth hormone and appetite simultaneously.

These implications remain largely theoretical. Most ghrelin resistance research has focused on appetite and weight regulation. The non-appetite consequences of central ghrelin resistance represent a significant gap in the evidence base.

Therapeutic Targeting: Where the Science Stands

The ghrelin resistance literature suggests several therapeutic strategies, though none has reached clinical practice specifically for this indication.

GOAT inhibitors would reduce acyl-ghrelin production while preserving des-acyl ghrelin. In the context of weight loss maintenance, GOAT inhibition could theoretically prevent the ghrelin rebound that drives weight regain. A phase 1 trial of the GOAT inhibitor BI 1356225 in overweight and obese subjects has been conducted, establishing early safety and pharmacokinetic data, but efficacy data for weight loss maintenance is lacking.

Ghrelin receptor neutral antagonists would block ghrelin-induced signaling without affecting the receptor's constitutive activity. This approach could reduce appetite without disrupting baseline GHS-R1A functions that may serve homeostatic purposes.

Anti-inflammatory strategies targeting hypothalamic and vagal inflammation could theoretically restore ghrelin sensitivity. If ghrelin resistance is fundamentally an inflammatory problem, as Naznin et al. suggested, then resolving the inflammation should restore normal signaling. Whether existing anti-inflammatory agents can penetrate the blood-brain barrier at sufficient concentrations to achieve this remains unclear.

LEAP-2 modulation represents another theoretical angle. Reducing LEAP-2 levels or blocking its antagonism of GHS-R1A could restore ghrelin signaling in obesity. Whether this would be therapeutically useful depends on whether restoring ghrelin signaling in obesity would improve non-appetite functions (cognition, mood, GH release) without exacerbating weight gain.

For context on how ghrelin system dysfunction intersects with wasting conditions, see ghrelin for cachexia: can the hunger hormone help wasting patients?.

The Bottom Line

Ghrelin resistance in obesity operates through at least four layered mechanisms: reduced secretion, impaired blood-brain barrier transport, receptor downregulation, and NPY/AgRP neuron dysfunction, with inflammation as a central driver. The resistance is reversible with weight loss, which paradoxically restores the hunger signal at exactly the wrong time for weight maintenance. Whether restoring ghrelin signaling in obesity could improve cognitive, mood, and growth hormone outcomes without promoting weight gain remains an open question.

Frequently Asked Questions

Why is ghrelin low in obese people if it causes hunger?

Ghrelin is suppressed in obesity primarily by elevated insulin levels. McLaughlin et al. (2004) showed that insulin-resistant obese adults had 39% lower ghrelin than equally obese insulin-sensitive controls, demonstrating that hyperinsulinemia independently suppresses ghrelin secretion. The body also reduces ghrelin as part of a feedback mechanism to limit further weight gain, though this defense is clearly insufficient to prevent obesity.

What is ghrelin resistance and how does it develop?

Ghrelin resistance is a state where the brain no longer responds normally to ghrelin's appetite and growth hormone-stimulating signals. It develops through multiple mechanisms during obesity: reduced circulating ghrelin, inflammation of the vagal afferent nerve and hypothalamus, downregulation of ghrelin receptors (GHSR), and impaired NPY/AgRP neuron responsiveness. Briggs et al. (2010) showed that even direct brain injection of ghrelin fails to stimulate appetite in diet-induced obese mice.

Can ghrelin resistance be reversed?

Yes. Perreault et al. (2004) demonstrated in mice that ghrelin resistance reverses with weight loss, restoring both normal ghrelin secretion patterns and brain sensitivity to ghrelin. This reversal contributes to post-diet weight regain because the restored hunger signal drives increased food intake at precisely the point when caloric restriction needs to be maintained.

Is ghrelin resistance the same as leptin resistance?

Ghrelin resistance and leptin resistance are distinct phenomena that co-occur in obesity. Leptin resistance means the brain fails to register satiety signals from fat tissue. Ghrelin resistance means the brain's hunger-signaling apparatus becomes dysfunctional. Both involve hypothalamic inflammation and impaired receptor signaling, but they affect different hormones with opposite functions. Cui et al. (2017) reviewed both conditions together in Nature Reviews Endocrinology, noting shared inflammatory mechanisms.

Does ghrelin resistance affect the brain beyond appetite?

Ghrelin regulates cognitive function, mood, growth hormone release, and neuroprotection in addition to appetite. Briggs et al. (2010) confirmed that ghrelin resistance in obesity is not confined to appetite circuits: ghrelin also fails to stimulate growth hormone secretion in obese mice. This raises the possibility that central ghrelin resistance contributes to obesity-associated cognitive decline, depression risk, and reduced growth hormone levels, though these connections need direct investigation.

Does weight loss surgery affect ghrelin resistance?

Sleeve gastrectomy removes the gastric fundus where most ghrelin-producing cells are located, physically reducing ghrelin production. This prevents the ghrelin rebound seen after dietary weight loss, which may partly explain the greater durability of surgical weight loss. Roux-en-Y gastric bypass has more variable effects on ghrelin depending on how much fundus tissue is preserved.